Search Results - "Grandin, E Wilson"

Refine Results
  1. 1

    Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis by Nunez, Jose I., Gosling, Andre F., O’Gara, Brian, Kennedy, Kevin F., Rycus, Peter, Abrams, Darryl, Brodie, Daniel, Shaefi, Shahzad, Garan, A. Reshad, Grandin, E. Wilson

    Published in Intensive care medicine (01-02-2022)
    “…Purpose This study aimed at analyzing the prevalence, mortality association, and risk factors for bleeding and thrombosis events (BTEs) among adults supported…”
    Get full text
    Journal Article
  2. 2

    Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation by Grandin, E. Wilson, Nunez, Jose I., Willar, Brooks, Kennedy, Kevin, Rycus, Peter, Tonna, Joseph E., Kapur, Navin K., Shaefi, Shahzad, Garan, A. Reshad

    “…Venoarterial extracorporeal membrane oxygenation (VA-ECMO) increases left ventricular (LV) afterload, potentially provoking LV distention and impairing…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma by Grandin, E. Wilson, MD, MPH, Ky, Bonnie, MD, MSCE, Cornell, R. Frank, MD, Carver, Joseph, MD, Lenihan, Daniel J., MD

    Published in Journal of cardiac failure (01-02-2015)
    “…Abstract Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency to treat patients with relapsed and/or refractory…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Conventional versus restricted anti‐Xa‐guided heparin protocol in adult patients undergoing extracorporeal membrane oxygenation by Alkazemi, Afrah, Eche, Ifeoma Mary, Adra, May, Cabezas, Fausto, Patel, Parth, Rick, Katelyn, Grandin, E. Wilson

    Published in Artificial organs (01-01-2022)
    “…Objective The optimal intensity of anticoagulation for adult patients supported with extracorporeal membrane oxygenation (ECMO) remains uncertain. The…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Relation of Body Mass Index to Long-Term Survival after Cardiac Resynchronization Therapy by Grandin, E. Wilson, MD, MPH, Wand, Alison, MD, Zamani, Payman, MD, MTR, Rame, J. Eduardo, MD, MPhil, Verdino, Ralph J., MD

    Published in The American journal of cardiology (15-12-2016)
    “…Abstract Obesity confers a paradoxical survival benefit among patients with heart failure (HF), but this obesity paradox has not been well established in…”
    Get full text
    Journal Article
  10. 10

    Heart Rate Dependence of the Pulmonary Resistance x Compliance (RC) Time and Impact on Right Ventricular Load by Metkus, Thomas S, Mullin, Christopher J, Grandin, E Wilson, Rame, J Eduardo, Tampakakis, Emmanouil, Hsu, Steven, Kolb, Todd M, Damico, Rachel, Hassoun, Paul M, Kass, David A, Mathai, Stephen C, Tedford, Ryan J

    Published in PloS one (18-11-2016)
    “…The effect of heart rate (HR) and body surface area (BSA) on pulmonary RC time and right ventricular (RV) load is unknown. To determine the association of HR…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch? by Grandin, E. Wilson, Teuteberg, Jeffrey J.

    Published in ESC Heart Failure (01-08-2021)
    “…[...]uncertainty exists about which patients are mostly likely to benefit, and the optimal timing, dosing, and duration of therapy have not been established…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Fulminant cardiac sarcoidosis resembling giant cell myocarditis: a case report by Jiang, Ginger Y, Cai, Qizhe, Grandin, E Wilson, Sabe, Marwa A

    Published in European heart journal : case reports (01-03-2021)
    “…Abstract Background Severe cardiac sarcoidosis (CS) can share clinical and histopathologic features with giant cell myocarditis (GCM). Case summary A…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report by Brinkley, D. Marshall, Wang, Li, Yu, Chang, Grandin, E. Wilson, Kiernan, Michael S.

    “…Inhibition of the renin angiotensin aldosterone system (RAAS) improves survival and reduces adverse cardiac events in heart failure with reduced ejection…”
    Get full text
    Journal Article